We are live on ! Find out more
RLMD icon

Relmada Therapeutics

49 hedge funds and large institutions have $4.36M invested in Relmada Therapeutics in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 20 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more call options, than puts

Call options by funds: $340K | Put options by funds: $131K

13.17% less ownership

Funds ownership: 41.02% → 27.85% (-13%)

29% less funds holding

Funds holding: 69 → 49 (-20)

50% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 20

82% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 28

87% less capital inflows, than outflows

Capital inflows: $1.83M | Capital outflows: $13.8M

Holders
49
Holders Change
-20
Holders Change %
-28.99%
% of All Funds
0.64%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
10
Reduced
20
Closed
28
Calls
$340​K
Puts
$131​K
Net Calls
+$209​K
Net Calls Change
-⁠$943​K

RLMD Hedge Fund Activity: Q4 2024 in Review

49 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2024, worth a combined $4.36M — down 89% from $40.1M a quarter earlier.

Sellers outnumbered buyers: 28 funds closed out of RLMD and 5 opened new positions — a net loss of 23 holders — while 20 trimmed existing stakes and 10 added.

The largest buyer was Tang Capital Management, adding an estimated $366K. The largest seller was Deep Track Capital, exiting entirely with an estimated $2.19M sold.

  • 49 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2024, down from 69 in Q3 2024.
  • Funds reported $4.36M of Relmada Therapeutics stock for Q4 2024, down 89% quarter-over-quarter.
  • 5 funds opened new Relmada Therapeutics positions in Q4 2024 and 28 closed out, a net change of -23 holders.
  • The largest Relmada Therapeutics buyer in Q4 2024 was Tang Capital Management, an estimated $366K added.
  • The largest Relmada Therapeutics seller in Q4 2024 was Deep Track Capital, an estimated $2.19M sold.

Based on aggregated 13F filings for Q4 2024.